All PlansCoverageMedium impact
Intensity-Modulated Radiotherapy (IMRT): Prostate
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Radiology, Urology·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes coverage criteria for Intensity-Modulated Radiotherapy (IMRT) for prostate cancer treatment. IMRT is considered medically necessary for localized prostate cancer and post-prostatectomy adjuvant or salvage therapy when specific clinical criteria are met, but investigational when criteria are not satisfied.
Action Required
Immediately: Billing team must verify that IMRT claims for prostate cancer include documentation supporting localized prostate cancer diagnosis (T1-T2N0-NXM0 or T3a-T3bN0-NXM0) or post-prostatectomy indications with adverse pathologic findings. Create checklist for radiation oncology staff to document medical necessity criteria before submitting claims. Claims not meeting policy criteria may be denied as investigational.